Hypericin diagnostic and therapeutic - Sanochemia

Drug Profile

Hypericin diagnostic and therapeutic - Sanochemia

Alternative Names: Polyvinylpyrrolidone-hypericin; Povidone-hypericin; PVP-hypericin; SPH-3542; Vidon

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator Planta Natural Products
  • Developer Austrian Academy of Sciences; Sanochemia Pharmazeutika
  • Class Anthraquinones; Anti-inflammatories; Antidepressants; Antipsoriatics; Antivirals; Cytostatics; Diagnostic agents; Perylenes; Polycyclic compounds; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Bladder cancer

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 30 Jul 2015 Preclinical development for Bladder cancer (Treatment) is ongoing in Austria
  • 31 May 2015 Hypericin (Bladder cancer diagnostic) - Sanochemia is available for licensing as of 31 May 2015. http://www.sanochemia.at
  • 19 Jul 2014 Sanochemia completes a phase II trial in Bladder cancer (Dignosis) in Austria and Germany (EudraCT2011-001819-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top